RECRUITINGPhase 1INTERVENTIONAL
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
About This Trial
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Who May Be Eligible (Plain English)
Who May Qualify:
- Have no significant body weight change for the 3 months prior to screening
Part A and Part E:
- Are considered healthy
- Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
Part B:
- Have a BMI of 27 to 45 kg/m2 at screening
Part C:
- Have a BMI of 25 to 45 kg/m2 at screening
Part D:
- Have type 2 diabetes
- Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening
- Have a BMI of 27 to 45 kg/m2 at screening
Who Should NOT Join This Trial:
- Have had an acute cardiovascular condition within the past 6 months prior to screening
- Have liver disease or pancreatitis
- Have used medications for weight loss within the 3 months prior to screening
Parts A, B, C, E:
- Have any form of diabetes
Part D:
- Have type 1 diabetes
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Have no significant body weight change for the 3 months prior to screening
Part A and Part E:
* Are considered healthy
* Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
Part B:
* Have a BMI of 27 to 45 kg/m2 at screening
Part C:
* Have a BMI of 25 to 45 kg/m2 at screening
Part D:
* Have type 2 diabetes
* Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening
* Have a BMI of 27 to 45 kg/m2 at screening
Exclusion Criteria:
* Have had an acute cardiovascular condition within the past 6 months prior to screening
* Have liver disease or pancreatitis
* Have used medications for weight loss within the 3 months prior to screening
Parts A, B, C, E:
* Have any form of diabetes
Part D:
* Have type 1 diabetes
Treatments Being Tested
DRUG
LY4086940
Administered orally
DRUG
Placebo
Administered orally
DRUG
LY4086940
Administered IV
Locations (5)
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore